Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

@article{Ryan2006ZoledronicAI,
  title={Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.},
  author={Christopher W. Ryan and Dezheng Huo and Laurence M. Demers and Tomasz M. Beer and Leo V Lacerna},
  journal={The Journal of urology},
  year={2006},
  volume={176 3},
  pages={972-8; discussion 978}
}
PURPOSE Androgen deprivation therapy in patients with prostate cancer is associated with bone loss and an increased risk of fractures. Zoledronic acid protects against bone mineral density loss when initiated concurrently with androgen deprivation therapy. We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover. MATERIALS AND METHODS Patients with prostate cancer without bone metastases… CONTINUE READING